Lead Program Opportunity Shattuck's lead program SL-325 targets TL1A/DR3, a first-in-class approach for IBD and inflammatory autoimmune diseases, signaling strong opportunities for strategic collaborations, licensing, or joint development with pharma partners seeking innovative TNF receptor pathway therapies.

Funding & Outreach With active conference participation and reported funding, Shattuck appears primed for out-licensing discussions, co-development deals, or services partnerships to advance its preclinical and clinical programs.

Regional Presence Dual offices in Austin and Durham position Shattuck to leverage regional CRO/CMO ecosystems and regulatory expertise, enabling localized collaboration for preclinical studies, manufacturing, and clinical development services.

Technical Expertise Expertise in protein engineering and TNF receptor biology suggests a need for advanced partnering in antibody discovery, optimization, biomarker strategy, and translational research support throughout early development.

Outsourcing Readiness As a mid-sized biotech with a focused inflammatory disease program, Shattuck is likely seeking flexible outsourcing partners for early-stage research, IND-enabling studies, and eventual GMP manufacturing as it advances toward clinical milestones.